Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$15.40 USD

15.40
1,385,256

-0.18 (-1.16%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $15.39 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should You Buy Tandem Diabetes Care (TNDM) Ahead of Earnings?

by Zacks Equity Research

Tandem Diabetes Care (TNDM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Zacks Equity Research

What's in Store for GW Pharmaceuticals' (GWPH) Q4 Earnings?

by Zacks Equity Research

GW Pharmaceuticals (GWPH) Q4 results likely to reflect top-line growth on strong adoption of Epidiolex and Sativex.

Sweta Killa headshot

5 Top-Ranked Stocks Beating the Market at Midway Q1

by Sweta Killa

Better-than-expected earnings, positive development in the U.S.-China trade relationship, China stimulus measures, easing policies and slew of upbeat economic data buoyed the stocks.

Nalak Das headshot

5 High-Flying Stocks Set to Beat on Q4 Earnings Next Week

by Nalak Das

Fourth-quarter 2019 earnings results have been improving significantly.

Zacks Equity Research

What's in Store for SmileDirectClub's (SDC) Q4 Earnings?

by Zacks Equity Research

SmileDirectClub (SDC) is likely to have gained from a strong international presence in Q4.

Zacks Equity Research

Tandem Diabetes Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Tandem Diabetes (TNDM) is optimistic about maintaining growth momentum on several recent developments.

Zacks Equity Research

Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?

by Zacks Equity Research

Consistent contribution from Henry Schein One is likely to have benefited Henry Schein's (HSIC) Q4 performance.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Tandem Diabetes (TNDM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Tandem Diabetes (TNDM) stock based on the movements in the options market lately.

Trina Mukherjee headshot

3 Medical Product Stocks Likely to Beat This Earnings Season

by Trina Mukherjee

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Zacks Equity Research

Sonoco (SON) Meets Q4 Earnings Estimates

by Zacks Equity Research

Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HealthEquity (HQY) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.

Zacks Equity Research

InMode (INMD) to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

InMode's (INMD) Q4 performance is likely to have been driven by developments in business segments.

Zacks Equity Research

Medtronic (MDT) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.

Zacks Equity Research

Will Tandem Diabetes Care Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Tandem Diabetes.

Zacks Equity Research

Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?

by Zacks Equity Research

Expanded claims volume and better purchasing economics are expected to have aided CVS Health's (CVS) top line in Q4.

Zacks Equity Research

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter earnings are likely to reflect top-line growth and rising global awareness of the company's real-time CGM.

Zacks Equity Research

Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings

by Zacks Equity Research

Key acquisitions are expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal third quarter

Zacks Equity Research

Molina Healthcare (MOH) to Post Q4 Earnings: What to Expect

by Zacks Equity Research

Molina Healthcare's (MOH) fourth-quarter results are likely to reflect lower premium revenues and decline in medical membership.

Zacks Equity Research

What's in the Offing for LabCorp's (LH) Earnings in Q4?

by Zacks Equity Research

With near-term visibility seeming bleak at the moment, we anticipate PAMA to once again dent LabCorp's (LH) fourth-quarter top line.

Zacks Equity Research

What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?

by Zacks Equity Research

Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.

Zacks Equity Research

Is a Beat in the Cards for Humana's (HUM) Earnings in Q4?

by Zacks Equity Research

Humana's (HUM) fourth-quarter results are likely to reflect lower membership, partly offset by higher revenues.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Agilysys, Tandem Diabetes Care, Enphase Energy, Forterra and MagnaChip Semiconductor

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Agilysys, Tandem Diabetes Care, Enphase Energy, Forterra and MagnaChip Semiconductor

Nalak Das headshot

5 Top-Ranked Growth Stocks for February That Have Jumped YTD

by Nalak Das

Several positive factors have strengthened investors' confidence in risky assets like equities. A few top-ranked growth stocks surged in January and still have strong upside left.

Zacks Equity Research

Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?

by Zacks Equity Research

Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.

Zacks Equity Research

What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?

by Zacks Equity Research

Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.